Genitourinary Cancers Symposium

The latest news from ASCO GU, including researcher interviews and physician perspective.


Meeting News

Talazoparib active, safe among subset of men with metastatic prostate cancer

February 25, 2020
Talazoparib monotherapy induced promising antitumor activity in men with metastatic castration-resistant prostate cancer who previously received…
Meeting NewsPerspective

Subsequent PFS benefit of apalutamide ‘an indicator of effective early intensive treatment’ in prostate cancer

February 24, 2020
The addition of apalutamide to androgen deprivation therapy provided a subsequent PFS benefit for men with nonmetastatic castration-resistant…
Meeting NewsPerspective

De-escalation chemotherapy after negative PET scan appears safe in low-volume metastatic seminoma

February 24, 2020
De-escalation of treatment after two cycles of chemotherapy and a negative PET scan appeared safe and feasible among a cohort of men with low-volume…
Meeting NewsPerspective

Novel small-molecule inhibitor ‘quite promising’ in advanced kidney cancer

February 18, 2020
MK-6482 appeared well-tolerated and showed promising single-agent activity among heavily pretreated patients with clear cell renal cell carcinoma…
Meeting NewsPerspective

Pembrolizumab plus olaparib safe, active in docetaxel-pretreated men with prostate cancer

February 28, 2019
SAN FRANCISCO — The combination of pembrolizumab and olaparib demonstrated activity in men with metastatic castration-resistant prostate cancer…
Meeting News

Nivolumab, ipilimumab combination shows durable benefit for advanced kidney cancer

February 21, 2019
SAN FRANCISCO — The OS and objective response rate benefits of nivolumab and ipilimumab compared with sunitinib persisted long-term among…
Meeting News

Atezolizumab plus bevacizumab safe, active in non-clear cell, sarcomatoid kidney cancer

February 21, 2019
SAN FRANCISCO — The combination of atezolizumab and bevacizumab demonstrated antitumor activity and appeared safe in patients with non-clear…
Meeting News

Hormone therapies for prostate cancer benefit black men more than white men

February 20, 2019
SAN FRANCISCO — Chemotherapy-naive black men with metastatic castration-resistant
Meeting News

Cytotoxic chemotherapy for testicular cancer linked to increased body fat

February 20, 2019
SAN FRANCISCO — Young men with metastatic testicular cancer who underwent cytotoxic chemotherapy experienced increases in
Meeting News

First-line avelumab, axitinib benefit persists across advanced kidney cancer patient subgroups

February 19, 2019
SAN FRANCISCO — The combination of avelumab and axitinib induced longer PFS and higher objective response rates than sunitinib among previously…